Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Galderma S.A.
Deal Watch: Novartis Acquires Gene Therapy Candidate From AvroBio
AvroBio retains rights to its other HSC gene therapy candidates. Alimera Acquires Further Commercial Rights To Eyepoint’s Uveitis Drug.
Almirall On Alert As Lebrikizumab Approval Date Approaches
The Barcelona-based group is confident that Lilly-partnered lebrikizumab has the potential to become a best-in-class treatment for atopic dermatitis and take market share from Sanofi’s blockbuster Dupixent.
Deal Watch: Japan’s JCR Inks Pacts With Sumitomo Dainippon, Alexion
Agreement with Alexion is JCR’s first international deal for its blood-brain barrier drug delivery technology. Sartoris buys PolyPlus from private equity investors.
Finance Watch: Another VC Mega-Round As Flare Raises $123m Series B
Private Company Edition: Flare Therapeutics, targeting transcription factors to discover precision medicines, had big pharma backing for its second venture capital financing. Also, Mediar closed a $10m series A round, Switch launched with $52m and EpiBiologics raised a $50m series A round.
- OTC, Consumer
- Other Names / Subsidiaries
- Alastin Skincare, Inc.
- CollaGenex Pharmaceuticals, Inc., Nestle S.A.
- Nestle Skin Health S.A.
- Spirig Pharma AG
- Q-Med AB
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.